… impact of the 3 FDA-approved PARP inhibitors on … ultimately analyzed 6 randomized controlled trials (RCTs), containing 2194 patients … RCTs, including the therapeutic medicines used, median follow-up … As for safety outcomes, treatment with olaparib (OR, 2.40; …

… breast cancer. This novel treatment combination offers what is … Therapeutics, which combined its drug candidate, paxalisib, with … (ADP-ribose) polymerase inhibitor olaparib (LYNPARZA), when used in … major advance in precision medicine by offering a faster …

… trials continue to explore new combinations of drugs … on personalized medicine, tailoring treatments to individual … , such as olaparib, has marked … treatment options. Collaborations between academic institutions, government agencies, and pharmaceutical …

… covers the active pharmaceutical ingredient, olaparib. The recent wave … US Food and Drug Administration (FDA) approval to … AstraZeneca told Medscape Medical News that AstraZeneca … trial — it is the consumer who ultimately suffers by paying higher drug …

… 2024, Foundation Medicine received FDA approval for … Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, … acetate, enzalutamide, olaparib, rucaparib (for … treatment strategies. A growing number of pharmaceutical …

… during a routine scan, her doctor found two new tumors on … process of finding the right medication combination. She’s currently being … was being treated with Lynparza (olaparib), it does negatively affect white …

… the marketing authorisation for the medicinal product Imfinzi. The marketing authorisation … systemic therapy, followed by maintenance treatment with: Imfinzi as monotherapy in … (dMMR) Imfinzi in combination with olaparib in endometrial cancer that is …

… ribose polymerase (PARP) inhibitor maintenance treatment after first-line chemotherapy. However … limiting access to biomarker-driven treatment. Therefore, the researchers evaluated … approvals of the PARP inhibitor olaparib as a first-line maintenance …

… the ADRIATIC trial, Imfinzi has the potential to transform treatment for people … plus chemotherapy followed by Lynparza (olaparib) and Imfinzi is approved for … , development, and commercialisation of prescription medicines in oncology, rare diseases, and …

… licensing agreements with LaNova Medicines Ltd. (LaNova) … antibody-drug conjugate zilovertamab vedotin for the treatment … -007 Trial (Read Announcement) Vaccines Merck Announced FDA Acceptance … . (8) Includes Pharmaceutical products not individually shown …